Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Pulmonology
Gynecologic Oncology
Questions discussed in this category
Would you give checkpoint inhibitor therapy to a cancer patient with known dermatomyositis given the association of checkpoint inhibitor associated myocarditis, myasthenia gravis, and myositis?
6 Answers available
Are there known biomarkers predictive of IRAEs?
3 Answers available
When can abdominal surgery be safely performed for presumptive ovarian cancer in a patient with recent pulmonary emboli?
(Normal oxygenation and echo)
1 Answer available
What is your preferred steroid sparing therapy in a patient experiencing a severe checkpoint inhibitor toxicity and not responding to high dose IV steroids?
2 Answers available
13752
13751
14409
13488
Papers discussed in this category
Future Sci OA, 2020 Aug 03
A retrospective analysis of eosinophilia as a predictive marker of response and toxicity to cancer immunotherapy.
Cancer Treat Res Commun, 2022 Jul 01
Absolute eosinophil count predicts clinical outcomes and toxicity in non-small cell lung cancer patients treated with immunotherapy.
Trends Immunol, 2021 Mar 10
Predicting and Preventing Immune Checkpoint Inhibitor Toxicity: Targeting Cytokines.
Related Topics in Pulmonology
Lung Cancer
Breast Cancer
Head and Neck Cancers
Hematologic Malignancies
Radiation Oncology
Gynecologic Cancers
Palliation
Neuro-Oncology
Gastrointestinal Cancers
Melanoma/Skin Cancer